http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2014230304-B2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33c922e05f6133b7d72dbb849d77487d
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2086
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-41
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00
filingDate 2014-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2018-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_061d573645341afb2ae8bcf4587ce071
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38c080f727f9efebe4e004eac9cb9141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c87d5b7c05d4048203bdeafa06ac230
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71d40a6c96c1090e1b21f981f4f279ef
publicationDate 2018-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AU-2014230304-B2
titleOfInvention Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
abstract The present invention relates to a pharmaceutical composition including valsartan and rosuvastatin calcium as active ingredients, and a manufacturing method therefor. The pharmaceutical composition including valsartan and rosuvastatin calcium according to the present invention can alleviate side effects of the existing single preparations and simultaneously improve compliance of patients having a cardiovascular disease, a hyperlipidemic disease and a complex disease thereof, and increases treatment and prevention effects, and in particular, obtains synergistic effects in treating hyperlipidemia, and enhances the dissolution rate of valsartan and rosuvastatin calcium and treatment effects by granulating valsartan and mixing rosuvastatin calcium.
priorityDate 2013-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2322175-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448897384
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419489201
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID444374
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7054
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID12944
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426080742
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419503865
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ07203
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452788844
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60846
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP49262
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP14847
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID1401
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506512
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5362585
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID751795
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP49254
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415731092
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24441
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP48199
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID62726
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5460341
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO19062
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23665634
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP12245
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID396842
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419580671
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559505
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5282455
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP02742
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP19094
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP02741
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450470952
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID446157

Total number of triples: 66.